NCT00419536View on ClinicalTrials.gov

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

PHASE1TerminatedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 31, 2006

Conditions
Hormone Refractory Prostate Cancer Disease
Interventions
DRUG

LBH589

Trial Locations (3)

10021

Memorial Sloan Kettering Cancer Center, New York

63119

Washington University School of Medicine, St Louis

02115-6084

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY